<DOC>
	<DOCNO>NCT01888874</DOCNO>
	<brief_summary>- 595 patient suffer active rheumatoid arthritis despite continued treatment methotrexate evaluate improvement disease activity ( efficacy ) take GLPG0634 ( 3 different dos - 50mg , 100mg 200mg daily - , evaluate QD BID regimen ) match placebo 24 week . - During course study , patient also examine side effect may occur ( safety tolerability ) , amount GLPG0634 present blood ( Pharmacokinetics ) well effect GLPG0634 disease- mechanism action-related parameter blood ( Pharmacodynamics ) determine . Also , effect different dos dose regiment GLPG0634 administration subject ' disability , fatigue , quality life evaluate .</brief_summary>
	<brief_title>Dose-finding Study GLPG0634 add-on Methotrexate Active Rheumatoid Arthritis Patients ( DARWIN1 )</brief_title>
	<detailed_description>- Treatment duration 24 week total . - However , Week 12 , subject placebo achieve 20 % improvement swell joint count ( SJC66 ) tender joint count ( TJC68 ) re-randomized ( automatically via interactive voice/web response [ IXRS ] ) treatment receive GLPG0634 100 mg q.d . 50 mg b.i.d . dos blind fashion , subject 50 mg q.d . achieve 20 % improvement SJC66 TJC68 assign 100 mg q.d . subject 25 mg b.i.d . achieve 20 % improvement SJC66 TJC68 assign 50 mg b.i.d . All continue study Week 24 . - Subjects group maintain randomize treatment Week 24 .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>male female subject ≥18 year age , day signing inform consent , diagnosis RA since least 6 month meeting 2010 ACR/EULAR criterion RA ACR functional class IIII , ≥6 swell joint ( 66 joint count ) ≥8 tender joint ( 68 joint count ) Screening Baseline , Screening serum creactive protein ≥0.7 x upper limit laboratory normal range ( ULN ) , receive MTX ≥6 month stable dose ( 15 25 mg/week ) MTX least 4 week prior Screening willing continue current regimen duration study . Stable dos MTX low 10 mg/week allow documented evidence intolerance safety issue higher dos . current therapy diseasemodifying antirheumatic drug ( DMARD ) MTX , current previous RA treatment biologic DMARD , exception biologic DMARDs administer single clinical study set 6 month prior Screening ( 12 month rituximab B cell deplete agent ) , biologic DMARD effective , discontinue , due lack efficacy , previous treatment time cytotoxic agent , MTX , Screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Methotrexate insufficient responder</keyword>
</DOC>